| Drug General Information |
| Drug ID |
D0P9ED
|
| Former ID |
DNC007889
|
| Drug Name |
CMI-489
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C12H15ClN2
|
| Canonical SMILES |
CN1C2CCC1C(C2)C3=CN=C(C=C3)Cl
|
| InChI |
1S/C12H15ClN2/c1-15-9-3-4-11(15)10(6-9)8-2-5-12(13)14-7-8/h2,5,7,9-11H,3-4,6H2,1H3
|
| InChIKey |
HLNPMOXPJPCMLY-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Neuronal acetylcholine receptor protein, alpha-4 chain |
Target Info |
Inhibitor |
[1]
|
|---|
| Neuronal acetylcholine receptor protein, beta-2 chain |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Cholinergic synapse
|
|
Nicotine addictionhsa04080:Neuroactive ligand-receptor interaction
|
|
Nicotine addiction
|
|
PANTHER Pathway
|
Nicotinic acetylcholine receptor signaling pathway
|
|
Nicotine pharmacodynamics pathwayP00044:Nicotinic acetylcholine receptor signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Highly sodium permeable acetylcholine nicotinic receptors
|
|
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
|
|
Highly calcium permeable nicotinic acetylcholine receptorsR-HSA-629587:Highly sodium permeable acetylcholine nicotinic receptors
|
|
Highly calcium permeable nicotinic acetylcholine receptors
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Nicotine Activity on Dopaminergic NeuronsWP706:SIDS Susceptibility Pathways
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | J Med Chem. 2007 Dec 13;50(25):6383-91. Epub 2007 Nov 10.Synthesis and nicotinic acetylcholine receptor binding properties of bridged and fused ring analogues of epibatidine. |
|---|
